endTB (Expand New Drugs for TB) Observational Study: Treatment of MDR-TB with regimens containing bedaquiline or delamanid

Principal investigator

Helena Huerga
Purpose of study
Purpose of study

To describe patient outcomes and assess factors associated with unfavorable outcomes (treatment failure, lost to follow-up and death). To estimate the frequency of adverse events of clinical significance.

  • Concept
  • Protocol & ERB
  • Implementation
  • Completion
  • Archived

Study timeline

  • Note left by Holly Baker

    22nd May 2022  
  • Publication added by Holly Baker

    13th January 2022
    Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort Hewison, Catherine "–" Oxford University Press (OUP) (2022)
     
  • Publication added by Holly Baker

    24th July 2020
    Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study Franke, Molly F. "–" American Thoracic Society (2021)
     
  • Implementation
    5th June 2020
  • Principal investigator changed by Holly Baker

    27th May 2020

    Changed to “Helena Huerga”

  •  
  • Concept
    27th May 2020
  • Study created

    27th May 2020

Publications

  • Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study
    Franke, Molly F. "–" American Thoracic Society "(2021)"
  • Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
    Hewison, Catherine "–" Oxford University Press (OUP) "(2022)"